A procurement manager sent me two certificates of analysis for the same 9 mm short-thread screw cap. One came from the brand she had been buying for six years at $0.41 per cap. The other came from a “private label” supplier at $0.26. The lot release values were identical to three decimal places, including the 0.038 in septum thickness and the 1.2 N·m recommended torque. Both were true. Both caps came off the same cavity number at the same molder in Jiangsu, on the same day, from the same lot of PTFE-faced silicone. That is the entire OEM versus private label question in one sentence: the factory did not change, only the name on the bag. What differs between an OEM vial and a private label vial is not the part. It is who owns the tooling, who controls the recipe, who carries the liability, and who can change any of those three things without telling you.
People ask me the OEM vs private label oem vial difference as if there were a materials answer. There almost never is. If both suppliers buy from the same molder, the glass, the polymer, the annealing schedule, and the dimensional window are the same. The difference sits in three assets that exist above the physical part:
- Tooling ownership. Who paid for the mold, who holds the drawing, and who can take the mold to another press.
- Recipe control. Who signed the process specification, and who has the authority to revise it.
- Liability and change notification. Who is legally on the hook when a lot fails, and who is contractually obligated to tell you before something changes.
A private label arrangement is a branding transaction. A true OEM arrangement is a control transaction. Both can produce a good vial. Only one of them lets you decide what the vial will be in three years.
Who actually owns the mold decides everything downstream
Start every supplier conversation with one question: whose name is on the tooling drawing? The answer sorts the market faster than any price sheet.
Three tooling arrangements, three levels of control
Molder-owned tooling. The factory paid for the mold and owns the drawing. You are buying time on someone else’s asset. This is the most common arrangement behind private label, and it is not automatically bad. It is bad when the molder decides to run the tool at a shorter cycle to increase throughput, which changes the residual stress in the neck finish and, eventually, the dimensional drift on the thread. You find out when your crimper starts seating inconsistently. You will not find out from a notification, because there is no notification clause.
Customer-owned tooling. You paid for the mold. The drawing is yours, the mold is yours (or held in trust at the molder), and if the molder’s quality slips you can physically move the tool to another press. This is the arrangement that makes an OEM relationship real. The cost is real too: a 12-cavity injection mold for a 9 mm screw cap runs somewhere in the $18,000 to $45,000 range depending on cavitation, hot-runner design, and steel. A blow-mold or tubing tool for the vial body is a different order of magnitude. You do not buy tooling to save money on unit price. You buy it to own the recipe.
Shared or family tooling. The molder runs your part and three other customers’ parts in the same family mold, or the same tool produces several brand variants. This is common in closures and it is where most “why did my lot drift” stories come from. A change made for another customer’s part, a gate adjustment, a cooling-line reroute, lands on your part too.
What the drawing controls
If you own the drawing, you control the tolerances that matter to your method. On a 12 x 32 mm vial that means the 6.00 ± 0.10 mm neck OD, the 32.0 ± 0.5 mm body height, the 0.5 mm bottom thickness, and the concentricity that keeps the needle centered. If you do not own the drawing, you are accepting whatever the molder’s generic drawing says, and generic drawings are written to the loosest tolerance the market will accept. See how a real OEM vial spec sheet is laid out and compare it to what your private label supplier will actually put in writing. Most will not put tolerances in writing at all.
The recipe is the process specification, not the resin data sheet
Two molders can run the same resin through the same tool and produce different parts. The resin data sheet tells you what the polymer can do. The process specification tells you what the molder is actually doing to it: melt temperature, mold temperature, injection speed, pack pressure, hold time, cooling time, annealing profile. That document is the recipe, and it is the thing that private label arrangements usually hide.
On a 9 mm screw cap molded in high-density polyethylene, a mold-temperature shift of 10 °C changes the shrinkage enough to move the thread pitch by a few thousandths. A few thousandths is the difference between a cap that torque-seats at 1.2 N·m and one that backs off under autoclave. On a glass vial, the annealing lehr profile controls the residual stress that decides whether the vial survives a 121 °C autoclave cycle or cracks at the shoulder. Neither of these is a resin property. Both are recipe properties.
Who can revise the recipe, and who has to tell you
In a real OEM arrangement, the process specification is a controlled document with a revision number, and the change-notification clause requires the molder to tell you before a revision takes effect. In a private label arrangement, the molder can revise the recipe whenever it wants and the brand owner may not even know, let alone you. The brand owner is buying finished parts and reselling them. The recipe is one layer below the brand owner’s visibility.
I have watched this play out. A lab qualified a private label closure against a 12-month stability program, then six months later started seeing septa that coring-tested at 1.5 punctures instead of the qualified 6. The molder had switched a silicone preform supplier to save cost. The brand owner did not know. The lab found out by running a puncture-count study, which is the only way to find out. If your supplier cannot produce a signed process specification with a revision history, you are buying parts, not a recipe.
When the brand changes but the factory does not, four things move
This is the scenario the whole article is about: same factory, new label. Four things change even though the part does not.
1. The specification you can hold someone to
An OEM agreement typically includes a locked specification, an inspection plan, an AQL level, and a defined method for resolving disputes. A private label agreement typically includes a purchase order and a data sheet. When the part drifts, the OEM buyer has a document to point at. The private label buyer has a conversation. The difference is not the part; it is the paper behind the part.
2. The change-notification obligation
A proper OEM contract requires written notice, often 90 days or more, before any change to material, process, tooling, or manufacturing site. That clause is worth more than any unit-price concession. A site transfer from one molder to another, even within the same supplier group, can move a dimensional value by more than the entire tolerance window on a 12 x 32 mm vial. Without notification, you discover it at the instrument, in a failed sequence, at 2 a.m.
3. The traceability chain
OEM arrangements usually carry lot-level traceability back to resin lot and mold cavity. Private label arrangements often stop at the brand owner’s lot number, which is a repack number, not a manufacturing lot. When an auditor asks for the traceability chain, a repack number is a dead end. The chain has to reach the molder, and the molder has to be willing to open the record. Only one of the two arrangements obligates them to.
4. The liability surface
If a closure leaches a compound that ruins a validated method, who pays? In an OEM arrangement, the specification and the change-notification clause create a documented basis for a claim. In a private label arrangement, the brand owner is often a reseller with limited technical staff and no access to the molder’s records. The liability exists either way. What differs is whether you can prove it.
Comparison: what you are actually buying in each arrangement
| Attribute | True OEM | Private label |
|---|---|---|
| Tooling owner | You (or held in trust) | Molder or brand owner |
| Drawing control | Yours, with tolerances | Supplier’s generic drawing |
| Process specification | Controlled, revision-tracked | Usually not disclosed |
| Change notification | Contractual, 90 days typical | None or informal |
| Traceability depth | Resin lot and cavity | Repack lot only |
| Typical neck OD tolerance | ± 0.10 mm | ± 0.20 mm or unstated |
| Septum thickness spec | 0.038 in ± 0.002 in | Nominal only |
| Torque recommendation | Documented, e.g. 1.2 N·m | Not stated |
| Puncture-count qualification | Method on file | Rarely available |
| Who you call when a lot fails | The molder, with records | The reseller, who calls the molder |
Read that table as a decision checklist. If the supplier cannot tick the first six rows, the price difference you are negotiating is not a discount. It is a transfer of risk to you.
Field case one: the cap that drifted at the crimp station
Symptom. A lab running EPA method work on a chromatography vial line started seeing intermittent crimp failures. About 1 in 400 caps did not seal, and the failures clustered on certain shifts. The lab blamed the crimper and replaced it.
Measurement. The crimper was fine. A dimensional study on 200 caps from three lots found the neck OD on the failing lot ran 6.18 mm against a 6.10 mm upper limit. The lot had been molded on a different press after the molder moved production. No notification was sent because the brand owner did not have a notification clause and the molder did not have a reason to volunteer one.
Fix. The lab moved to an OEM arrangement with customer-owned tooling and a 90-day change-notification clause. The molder now runs the part on the qualified press only, and a first-article inspection on every lot checks neck OD at 6.00 ± 0.10 mm. Crimp failures dropped to zero over the next 18 months. The unit price went up. The cost of rework went away.
Field case two: the septum that changed under a stability protocol
Symptom. A pharmaceutical QC lab qualified a private label screw cap for a 12-month stability program. At month 6, several lots showed extractable peaks in the 210 to 230 nm range that were not present at qualification. The method had not changed. The instrument had not changed.
Measurement. The lab ran a controlled extraction on retained samples from both the qualification lot and the current lot. The current lot’s silicone septum released a different oligomer profile. A puncture-count study showed the current lot averaged 3.2 punctures before coring, against 6.1 at qualification. The septum formulation had changed. The brand owner had not been told.
Fix. The lab moved to an OEM arrangement with a locked formulation, a documented extraction method, and a stability clause that requires re-qualification before any material change. The lesson: a private label qualification qualifies a lot. An OEM qualification qualifies a specification. Only one survives a supplier’s cost-reduction cycle.
How to tell which one you are actually buying
Ask these five questions. The answers sort the supplier in under ten minutes.
- Can I see the tooling drawing, and whose name is on it? A true OEM will show you. A private label will not, because the drawing belongs to someone else.
- Can I see the process specification with revision number and date? If the answer is “that’s proprietary,” you are buying parts, not a recipe.
- What is your change-notification period, and is it in the contract? Anything under 30 days is not a notification. 90 days is the working standard for a consumable that feeds a validated method.
- Can you trace this lot back to the resin lot and the mold cavity? If the traceability stops at a repack number, the chain is broken.
- Who do I call when a lot fails, and do they have the records? If the answer is a reseller who has to call the molder, the liability is yours.
If the supplier is a true OEM, the answers will be documents you can read. If it is private label, the answers will be assurances. For a consumable that plugs into a validated method, documents beat assurances every time. Look at how a real OEM documents vial closures against the same questions and you will see the difference in about one page.
The decision rule
Buy OEM when the vial or closure is part of a validated method, when the method is regulated under EPA SW-846 or a pharmacopeial protocol, or when a dimensional drift of 0.10 mm would force a re-validation. Buy private label when the vial is a general-purpose container feeding a method that has no regulatory attachment and no stability commitment, and when you can absorb a silent change without re-qualifying anything. For anything in between, the honest answer is that you are paying for the paper, not the part, and the paper is what protects the method. If you want to see how the paper looks when it is done properly, the analytical testing literature on method transfer is the reference standard, and the major instrument vendors document their own consumable specifications to the same depth (see Agilent’s chromatography consumables, Thermo Fisher’s sample handling documentation, and Restek’s technical resources).
The decision rule in one line: if you cannot name the tooling owner and the revision number of the process specification, you are buying private label no matter what the box says, and the part you receive next quarter may not be the part you qualified this quarter. That is the only difference that matters, and it is worth more than the 15 cents per cap you thought you were saving.
References & further reading
Related resources from our lab consumables network:
- Oem Vial at oemsamplevials.com
- Vial Closures at vialclosures.com
- Analytical Testing at labanalyticaltesting.com
- Chromatography Vial at chromvials.com
External references and standards: